PatientsVille.com Logo

DEPRESSED MOOD and Ritalin

PatientsVille

DEPRESSED MOOD Symptoms and Causes

Everyone feels stressed from time to time. Not all stress is bad. All animals have a stress response, and it can be life-saving. But chronic stress can cause both physical and mental harm.

There are at least three different types of stress:

  • Routine stress related to the pressures of work, family, and other daily responsibilities
  • Stress brought about by a sudden negative change, such as losing a job, divorce, or illness
  • Traumatic stress, which happens when you are in danger of being seriously hurt or killed. Examples include a major accident, war, assault, or a natural disaster. This type of stress can cause post-traumatic stress disorder (PTSD).

Different people may feel stress in different ways. Some people experience digestive symptoms. Others may have headaches, sleeplessness, depressed mood, anger, and irritability. People under chronic stress get more frequent and severe viral infections, such as the flu or common cold. Vaccines, such as the flu shot, are less effective for them.

Some people cope with stress more effectively than others. It's important to know your limits when it comes to stress, so you can avoid more serious health effects.

NIH: National Institute of Mental Health

Check out the latest treatments for DEPRESSED MOOD

DEPRESSED MOOD treatment research studies

Ritalin clinical trials, surveys and public health registries


Find Drug Side Effect reports



Ritalin Side Effects

Depression (131)
Aggression (111)
Agitation (101)
Headache (94)
Anxiety (88)
Abnormal Behaviour (80)
Disturbance In Attention (79)
Feeling Abnormal (77)
Nausea (76)
Insomnia (66)
Decreased Appetite (60)
Dizziness (56)
Suicidal Ideation (53)
Dyspnoea (51)
Hyperhidrosis (50)
Fatigue (48)
Tremor (47)
Hallucination (46)
Irritability (46)
Weight Decreased (46)
Somnolence (46)
Hypertension (45)
Confusional State (45)
Vomiting (44)
Tachycardia (44)
Malaise (43)
Suicide Attempt (41)
Nervousness (40)
Convulsion (39)
Hallucination, Auditory (39)
Attention Deficit/hyperactivity Disorder (38)
Bipolar Disorder (38)
Crying (37)
Heart Rate Increased (36)
Depressed Mood (36)
Memory Impairment (33)
Chest Pain (33)
Psychomotor Hyperactivity (33)
Pyrexia (33)
Fall (32)
Blood Pressure Increased (32)
Anorexia (32)
Loss Of Consciousness (31)
Psychotic Disorder (31)
Weight Increased (31)
Palpitations (30)
Abdominal Pain Upper (30)
Asthenia (29)
Blood Creatine Phosphokinase Increased (25)
Apathy (25)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

hi I have long use Leponex Clozapine (25 mg three times) my diagnosis F20.1 that would have some consequences that already 11 years receive I think it was not anything my doctor gave me the wrong diagnosis because that day was a bit depressed I wen

Have been on champix goin on 3 weeks,,have experienced foul taste in mouth,,crazy dreams,,IBS..Starting new business so the stomach issues could be nerves..I have not experienced any weird mood swings,,,The need to have a smoke is almost g

Thankyou for witing out this article I have been on 120mgs of Zeldox since November 2010 at first it seemed to work and now it has me stuck in a depression state . I was prior to that on olanzapine which held me also in a depressed state I

<b>Describe Your Ezetrol Experience Here:</b>Sleeplessness severe pain in muscles and joints nausea and abdominal pain headaches and pain behind eyes chronic fatigue and flat mood

Hey Michelle, we almost have the same issue..I switched from Yaz to Trinessa because I and my husband thought it caused my severe mood swings prior to my period. I have been running and working out but I start experiencing joint

hi there, could you help me with this, if you have experienced with Ventolin My sister felt so useless and depressed, so she took her<span style='color: #366388;'>ventolin inhalerand&

I have been using Nebido 1ml for 12 months now and have had no serious side effects in the first 3 to 6 months. Thereafter I gained weight and is now suffering severe and debilitating mood swings, ranging from uncontrollable rage

Since starting champix i have experienced severral side effects including: -increased urination -lower back pain -extreme fatigue -mood swings -decrease in sex drive

<strong></strong><span style='color: #808080;'>i took zopiclone becaouse i coulnd sleep ... but i felt depressed, i had bad feeling in my chest, my blood pressurewas too fast, sometimeswas difficult to breath for

<strong>Constipation, Fluid build up under my eyes, Depressed</strong>

DEPRESSED MOOD Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting A Study Comparing Long-acting Methylphenidate (ConcertaTM) vs. Placebo in the Treatment of Memory Loss Due to HIV
Condition: HIV Dementia
Interventions: Drug: Long acting methylphenidate;   Drug: Matched placebo
Outcome Measures: Change in rate of reaction time as measured by neuropsychological testing;   Number of Subjects with Adverse Events as Measures of Safety and Tolerability of Concerta in HIV infected adults
2 Recruiting Effects of Methylphenidate (Ritalin®) on the Neural Basis of Anxiety
Condition: PTSD
Interventions: Drug: Methylphenidate;   Drug: Placebo
Outcome Measures: Changes in blood oxygenation level-dependent BOLD signal responses;   Changes in BOLD signal responses;   Changes in skin conductance response;   Latency and accuracy during a interoceptive stimulus task
3 Not yet recruiting The Effect of Ritalin (Methylphenidate Hydrochloride) on Pain and Auditory Sensitivity: an Exploratory Double-blind Randomized Controlled Trial on Healthy Subjects
Condition: Pharmacological Action (PA)
Interventions: Drug: methylphenidate hydrochloride;   Drug: Sugar pill (placebo)
Outcome Measures: Experimental pain intensity measured on a visual analogue scale (0-100);   effect of Ritalin on auditory sensitivity, measured by the response to different auditory stimulations;   pain intensity (NPS 0-100) in response to thermal stimuli and the measures of the auditory tests.
4 Not yet recruiting Identifying Characteristic Signature of Attention Deficit / Hyperactivity Disorder (ADHD) and Ritalin Treatment
Condition: "Attention Deficit Hyperactivity Disorder"
Interventions: Drug: Ritalin;   Drug: Placebo
Outcome Measure: Resting oscillation activity and Event-related-Potentials in Attention Deficit / Hyperactivity Disorder (ADHD) and healthy subjects.
5 Not yet recruiting Dopamine Receptor Imaging to Predict Response to Stimulant Therapy in Chronic TBI
Condition: Traumatic Brain Injury
Interventions: Drug: methylphenidate;   Drug: Placebo
Outcome Measures: Relationship between tonic dopamine release (measured by displacement of [11C]-raclopride by oral methylphenidate) and change in processing speed between baseline and after methylphenidate treatment.;   Relationship between D2/D3 receptor availability in ventral striatum and prefrontal cortex and neuropsychologic deficits.;   Relationship between tonic dopamine release in the ventral striatum and prefrontal cortex with neuropsychologic deficits after TBI.;   Relationship between D2/D3 receptor availability and functional connectivity of the prefrontal cortex with nodes of the default mode network.;   Relationship between TMS-induced short-interval cortical inhibition of M1 and tonic dopamine release.;   Test motivation and reward on and off methylphenidate in TBI patients.
6 Unknown  Amantadine Versus Ritalin in the Treatment of Attention Deficit Hyperactivity Disorder (ADHD)
Condition: Attention Deficit Hyperactivity Disorder
Interventions: Drug: Amantadine;   Drug: Ritalin
Outcome Measure: The mean decrease in ADHD -RS-IV score from baseline will be used as the main outcome measure of response of ADHD treatment.
7 Recruiting Methylphenidate to Improve Balance and Walking in MS
Condition: Multiple Sclerosis
Interventions: Drug: Methylphenidate (Ritalin);   Drug: Placebo
Outcome Measures: Timed Up and Go time (TUG time);   Automatic Postural Response (APR) Latency (in sec);   Timed 25 Foot Walk (T25FW in secs);   Pittsburgh Sleep Quality Assessment Questionnaire score;   Modified Fatigue Index Scale score;   Vestibular-Ocular Reflex time (in secs)
8 Unknown  Study of Methylphenidate as Add on Therapy in Depressed Cancer Patients
Condition: Depression
Interventions: Drug: Methylphenidate;   Drug: Placebo
Outcome Measures: depressive symptoms;   Distress level
9 Recruiting Effects of Methylphenidate, Modafinil, and MDMA on Emotion-processing in Humans: A Pharmaco-fMRI Study
Conditions: Healthy;   Substance-related Disorder;   Mood Disorder
Interventions: Drug: Methylphenidate;   Drug: Modafinil;   Drug: MDMA;   Drug: Placebo
Outcome Measures: Effect on amygdala and striatum BOLD signal responses to emotional stimuli;   Effects on cognitive performance and associated BOLD signal changes in frontal areas;   Subjective effects;   Neuroendocrine effects;   Empathy and social behavior;   Physiological effects of methylphenidate, modafinil, and MDMA;   Genetic Polymorphisms;   Pharmacokinetics of methylphenidate, modafinil, and MDMA
10 Recruiting Methylphenidate vs. Risperidone for the Treatment of Children and Adolescents With ADHD and Disruptive Disorders
Conditions: Attention Deficit/Hyperactivity Disorder;   Oppositional Defiant Disorder;   Conduct Disorder
Interventions: Drug: Methylphenidate;   Drug: Risperidone
Outcome Measures: Change from baseline of aggressive behaviors.;   Clinical Global Impression - Improvement scale (CGI-I) questionnaire;   ADHD-RS questionnaire;   Children's Depression Rating Scale (CDRS) questionnaire;   Young Mania Rating Scale (YMRS) questionnaire;   Children Sleep Habits Questionnaire (CSHQ);   Clinical Global Impression - Severity (CGI-S) questionnaire
11 Recruiting The Effect of Methylphenidate Treatment in Familial Attention Deficit/Hyperactivity Disorder (ADHD)
Conditions: Attention Deficit/Hyperactivity Disorder Combined Type;   ADHD Predominantly Inattentive Type;   ADHD Predominantly Hyperactivity Type;   ADHD-not Other Specified
Intervention: Drug: Methylphenidate- Ritalin IR (Immediate Release)
Outcome Measures: Clinical Global Impression-Improvement scale;   overall ADHD-Rating Scale (ADHD-RS) score
12 Recruiting Methylphenidate as Treatment Option of Fatigue in Multiple Sclerosis
Conditions: Multiple Sclerosis;   Fatigue
Interventions: Drug: Methylphenidate modified release;   Drug: Maltodextrin
Outcome Measures: Change of Fatigue as measured by Fatigue Severity Scale;   Change of Fatigue as measured by Modified Fatigue Impact Scale (MFIS)
13 Not yet recruiting Methylphenidate on Intracortical Inhibition in Methamphetamine Abusers Attention Deficit Hyperactivity Disorder (ADHD)
Condition: Attention Deficit Hyperactivity Disorder
Intervention: Other: methylphenidate tablets and Inter-stimulus Intervals (ISI)
Outcome Measures: Conners ADHD Rating Scale;   Change of Motor Evoked Potential (MEP)
14 Recruiting Control of Cognition
Conditions: Healthy;   Attention Deficit Hyperactivity Disorder;   Alcohol Dependence;   Attention Deficit Hyperactivity Disorder and Alcohol Dependence
Interventions: Drug: Methylphendiate;   Drug: Naltrexone;   Drug: Placebo
Outcome Measures: Identify abnormalities in prefrontal control neural circuits underlying attention control, motor control, and appetitive control;   Characterize effects of methylphenidate and naltrexone on neural circuits in prefrontal cortex associated with attention control, motor control, and appetitive control;   Reaction time on the Multi-Source Interference Task;   Accuracy on the Multi-Source Interference Task;   Reaction time variability on the Multi-Source Interference Task
15 Recruiting Multimodal Therapy for Treatment of Fatigue
Condition: Prostate Cancer
Interventions: Other: Placebo;   Drug: Methylphenidate;   Behavioral: Counseling Sessions;   Other: Sham Exercise;   Other: Standardized Exercise Intervention Program;   Other: Cognitive Behavioral Therapy (CBT)
Outcome Measure: Change in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) subscale scores
16 Recruiting Methylphenidate for Attention Problems After Pediatric TBI
Conditions: Traumatic Brain Injury;   TBI;   ADHD
Interventions: Drug: Methylphenidate;   Drug: Placebo
Outcome Measures: Parent report measures;   Neuropsychological Testing;   Teacher Report Measures
17 Not yet recruiting Reversal of General Anesthesia With Methylphenidate
Conditions: Post Operative Cognitive Dysfunction;   Emergence From Anesthesia
Intervention: Drug: Methylphenidate
Outcome Measures: Number of Participants with Adverse Events as a Measure of Safety and Tolerability;   Time to emergence from general anesthesia
18 Recruiting Impact of CES1 Genotype on Metabolism of Methylphenidate
Conditions: Carboxylesterase 1 (CES1) Genotype;   CES1 Activity
Intervention: Drug: Methylphenidate
Outcome Measures: Plasma concentration of methylphenidate and Ritalinic acid;   Metabolomic Profile
19 Recruiting A Comparison of Methylphenidate and Cognitive Behavioural Therapy for the Treatment of Binge Eating Disorder
Condition: Binge-Eating Disorder
Interventions: Drug: Methylphenidate;   Behavioral: Cognitive Behavioral Therapy
Outcome Measures: Frequency of binge episodes/days, as assessed by prospective daily binge diary;   Frequency of objective binge episodes and overall illness severity, as assessed by both the Eating Disorder Examination Interview and Questionnaire;   Clinician impression of illness severity and improvement, as assessed by the Clinical Global Impression scale;   Quality of life, as assessed by the Quality of Life Inventory;   Associated features of binge eating as captured by the Dutch Eating Behavior Questionnaire and Binge Eating Scale;   Body Mass Index
20 Not yet recruiting Methylphenidate ER Liquid Formulation in Adults With ASD and ADHD
Conditions: Attention-deficit/Hyperactivity Disorder;   Autism Spectrum Disorder
Intervention: Drug: Methylphenidate extended-release liquid formulation
Outcome Measure: Adult ADHD Investigator Symptom Report Scale (AISRS)